Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

1.

Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.

Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH.

Arch Gen Psychiatry. 2012 Sep;69(9):952-61. doi: 10.1001/archgenpsychiatry.2011.2053.

PMID:
22945622
[PubMed - indexed for MEDLINE]
2.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30. Review.

PMID:
16735655
[PubMed - indexed for MEDLINE]
3.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
[PubMed - indexed for MEDLINE]
4.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
[PubMed - indexed for MEDLINE]
5.

Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.

Simpson D, Plosker GL.

CNS Drugs. 2004;18(6):397-401. Review.

PMID:
15089111
[PubMed - indexed for MEDLINE]
7.

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.

Simpson D, Plosker GL.

Drugs. 2004;64(2):205-22. Review.

PMID:
14717619
[PubMed - indexed for MEDLINE]
8.

Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.

Wigal SB, Chae S, Patel A, Steinberg-Epstein R.

Semin Pediatr Neurol. 2010 Dec;17(4):230-6. doi: 10.1016/j.spen.2010.10.005. Review.

PMID:
21183129
[PubMed - indexed for MEDLINE]
9.

A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.

Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ.

J Child Adolesc Psychopharmacol. 2013 Apr;23(3):179-93. doi: 10.1089/cap.2012.0093. Epub 2013 Apr 6. Review.

PMID:
23560600
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
[PubMed - indexed for MEDLINE]
11.

Attention deficit hyperactivity disorder in adults.

Rösler M, Casas M, Konofal E, Buitelaar J.

World J Biol Psychiatry. 2010 Aug;11(5):684-98. doi: 10.3109/15622975.2010.483249. Review.

PMID:
20521876
[PubMed - indexed for MEDLINE]
12.

Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.

Fredriksen M, Halmøy A, Faraone SV, Haavik J.

Eur Neuropsychopharmacol. 2013 Jun;23(6):508-27. doi: 10.1016/j.euroneuro.2012.07.016. Epub 2012 Aug 20. Review.

PMID:
22917983
[PubMed - indexed for MEDLINE]
13.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
[PubMed - indexed for MEDLINE]
14.

Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines.

Ramos-Quiroga JA, Montoya A, Kutzelnigg A, Deberdt W, Sobanski E.

Curr Med Res Opin. 2013 Sep;29(9):1093-104. doi: 10.1185/03007995.2013.812961. Epub 2013 Jul 2. Review. Erratum in: Curr Med Res Opin. 2013 Nov;29(11):1573.

PMID:
23742051
[PubMed - indexed for MEDLINE]
15.

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.

Santosh PJ, Sattar S, Canagaratnam M.

CNS Drugs. 2011 Sep 1;25(9):737-63. doi: 10.2165/11593070-000000000-00000. Review.

PMID:
21870887
[PubMed - indexed for MEDLINE]
16.

Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.

Christman AK, Fermo JD, Markowitz JS.

Pharmacotherapy. 2004 Aug;24(8):1020-36. Review.

PMID:
15338851
[PubMed - indexed for MEDLINE]
17.

[Structural and functional neuroanatomy of attention-deficit hyperactivity disorder (ADHD)].

Emond V, Joyal C, Poissant H.

Encephale. 2009 Apr;35(2):107-14. doi: 10.1016/j.encep.2008.01.005. Epub 2008 Jul 7. Review. French.

PMID:
19393378
[PubMed - indexed for MEDLINE]
18.

MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder.

Schweren LJ, de Zeeuw P, Durston S.

Eur Neuropsychopharmacol. 2013 Oct;23(10):1151-64. doi: 10.1016/j.euroneuro.2012.10.014. Epub 2012 Nov 17. Review.

PMID:
23165220
[PubMed - indexed for MEDLINE]
19.

Areas of the brain modulated by single-dose methylphenidate treatment in youth with ADHD during task-based fMRI: a systematic review.

Czerniak SM, Sikoglu EM, King JA, Kennedy DN, Mick E, Frazier J, Moore CM.

Harv Rev Psychiatry. 2013 May-Jun;21(3):151-62. doi: 10.1097/HRP.0b013e318293749e. Review.

PMID:
23660970
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies.

Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J.

J Clin Psychiatry. 2013 Sep;74(9):902-17. doi: 10.4088/JCP.12r08287. Review.

PMID:
24107764
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk